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Regulation between the fed and fasted states in mammals is partially controlled by peroxisome
proliferator-activated receptor-a (PPAR-a). Expression of the receptor is high in the liver, heart and
skeletal muscle, but decreases with age. A combined
1H nuclear magnetic resonance (NMR)
spectroscopy and gas chromatography-mass spectrometry metabolomic approach has been used to
examine metabolism in the liver, heart, skeletal muscle and adipose tissue in PPAR-a-null mice and
wild-typecontrolsduringageingbetween3and13months.ForthePPAR-a-nullmouse,multivariate
statistics highlighted hepatic steatosis, reductions in the concentrations of glucose and glycogen in
both theliverand muscle tissue, and profound changes inlipid metabolism ineach tissue, reﬂecting
known expression targets of the PPAR-a receptor. Hepatic glycogen and glucose also decreased with
age for both genotypes. These ﬁndings indicate the development of age-related hepatic steatosis in
the PPAR-a-null mouse, with the normal metabolic changes associated with ageing exacerbating
changes associated with genotype. Furthermore, the combined metabolomic and multivariate
statistics approach provides a robust method for examining the interaction between age and
genotype.
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Introduction
Fatty acids are able to stimulate their own catabolism through
a set of nuclear receptors called the peroxisome proliferator-
activated receptors (PPARs) (Keller et al, 1993), which control
the expression of a variety of genes involved in lipid
metabolism and energy homoeostasis (Dreyer et al, 1992;
Motojima et al, 1998; Berger and Moller, 2002). Of the three
PPAR isoforms that exist (PPAR-a,P P A R - d and PPAR-g), fatty
acids bind to PPAR-a with the greatest afﬁnity (Desvergne and
Wahli, 1999). PPAR-a is highly expressedin tissues with a high
catabolic rate such as the liver, kidneys, heart and skeletal
muscle (Braissant et al, 1996) and its activation results in
downstream transcription of genes controlling fatty acid
transport, uptake, intracellular binding and catabolism
(Issemann et al, 1992). PPAR-a is also activated by ﬁbrates, a
synthetic classofcompounds thatimprovemuscleandhepatic
insulin resistance, decrease the fat content of the liver and
reduce the circulating levels of non-esteriﬁed fatty acids
(NEFAs) in both rodents and humans (Guerre-Millo et al,
2000; Rubins et al, 2002).
Although the role of PPAR-a in regulating the transition
between the fed and fasted states, particularly in the liver, has
been widely investigated, its role in normal ageing has been
much less studied. However, PPAR-a expression is known to
decreaseina rangeof tissuesincludingthe liverand heartwith
age (Iemitsu et al, 2002; Sanguino et al, 2005; Ye et al, 2005).
The PPAR-a-null mouse (Lee et al, 1995) has considerably
aided research into the role of this receptor. The loss of PPAR-a
function results in increased circulating triacylglyceride
concentrations and fatty inﬁltration of the liver (Peters et al,
1997; Barak and Kim, 2007). However, most previous studies
have detected only these changes in the PPAR-a-null mouse
duringfasting(Kerstenetal,1999;Leoneetal,1999),whenthe
mice develop profound hypoglycaemia and severe lipid
accumulation in organs including the heart and liver (Djouadi
et al, 1998). The ketogenic response to low nutrient levels is
also lacking, resulting in insufﬁcient delivery of energy supply
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tions are documented to be secondary to an underlying defect
in fatty acid oxidation, which results from an inability to
increase b-oxidation under conditions of low glucose uptake,
ultimately leading to the observed energy deﬁcits in this
mouse (Le May et al, 2000). In contrast to these studies that
focus on animals under fasted conditions, we have previously
detected profound perturbations in glycolysis, gluconeogen-
esis, amino-acid metabolism and fatty acid metabolism in a
range of tissues in the PPAR-a-null mouse at 1 month when fed
ad libitum using a metabolomic-based approach (Atherton
et al, 2006). Metabolomics describes the comprehensive
analysis of the collection of small molecule metabolites
associated with a cell, tissue, organ or organism in a context-
dependent manner (Weckwerth, 2003; Grifﬁn, 2004), and has
been discriminatory even for mild or ‘silent phenotypes’ in a
range of organisms including man (Nicholson et al, 2002;
Dunn et al, 2005).
Inthisstudy,theinteractionsbetweensystemicmetabolism,
loss of PPAR-a and the age of the animal have been
investigated by a metabolomic investigation of the PPAR-a-
null mouse fed ad libitum based on
1H nuclear magnetic
resonance (NMR) and gas chromatography-mass spectro-
metry (GC-MS) in conjunction with multivariate statistics.
This approach has demonstrated a profound age-dependent
steatosisandlossofglycogenintheliveraswellasalteredfatty
acid metabolism in a number of tissues in the PPAR-a-null
mouse. The method also provides a template for other
metabolomic studies to investigate how age and genotype
interact to produce a given metabolic proﬁle.
Results
Loss of PPAR-a function results in severe
perturbations in glycolysis/gluconeogenesis
The metabolic deﬁcits of the PPAR-a-null mouse were most
evident in the liver where PPAR-a expression is highest in the
mouse. Using
1H-NMR spectroscopy, tissue had a decreased
glucose concentration relative to age-matched controls at all
time points (Figure 1A). By 13 months, the glucose concentra-
tion in the PPAR-a-null mice was 12.0±2.0% of that of the 3
month PPAR-a-null mice, and 15.2±1.4% of that in age-
matched controls. Subsequent application of PCA to all PPAR-
a-null data (3–13 months) demonstrated that this effect,
associated with ageing, was the dominant trend in the overall
data set (Figure 1B) and the reduction in glucose becomes
more pronounced with age (Figure 1C and D). This reduction
in glucose is also accompanied by a signiﬁcant decrease in
glycogen concentration (Figure 1D). Using partial least
squares (PLS) to model the metabolic changes associated with
ageing in the NMR spectroscopy data set of aqueous extracts
from the liver tissue, a robust predictive model was produced
for the control group (R
2(X)¼0.22; R
2(Y)¼0.72; Q
2¼0.70 for
the ﬁrst component; Figure 1E). This model passed cross-
validation according to random permutation of the Yvariable
(age) (Figure 1F). The correlation between these metabolic
changes and age were robust enough to allowthe prediction of
the age of individual animals according to their liver tissue
metabolic ﬁngerprints (Figure 1G). However, using the same
model to predict the age of the PPAR-a-null mice from their
liver tissue proﬁles as measured by NMR spectroscopy of the
aqueous extracts demonstrated that the 13-month-old animals
were predicted to be signiﬁcantly older (Po0.001; Student’s
t-test between predicted age of wild-type and mutant mice)
and in general PPAR-a-null mice were ﬁtted to be above the
line of the control mouse data. Reversing this analysis, control
animals were predicted to be younger than their actual age
according to a PLS model based on the metabolic changes
detected in the liver tissue of PPAR-a-null mice (data not
shown). The ageing trends for both mouse genotypes were
associated with decreases in glucose (d 3.46–3.90), leucine
and isoleucine (d 0.94–1.02) and increases in fatty acids (d
1.26–1.30); lactate (d 1.30–1.34); choline/phosphocholine (d
3.20) and taurine (d 3.24).
GC-MSanalysisofthelivertissuealsodemonstratedthatthe
liver from younger mice (3 and 5 months) could be
characterised by a decrease in the number of disaccharide
molecules relative to the control samples. Under conditions of
lowglucose/glycogen,itisknownthat lactateandaminoacids
represent important hepatic gluconeogenic substrates. As the
PPAR-a-null mouse ages, there is a signiﬁcant age-related
increase in the number of amino acids in the liver, including
alanine, aspartate and glutamate, as well as a signiﬁcant
increase in lactate (Figure 1H).
Analysis of other tissues revealed that the diaphragm, white
adipose tissue (WAT), heart and soleus skeletal muscle from
the PPAR-a-null mouse also demonstrated a decrease in the
concentration of glucose, which becomes more pronounced
with age, being most notable at 11–13 months (Figure 1I). In
these tissues, robust PLS models were also built of the age-
relatedchangesdetectedintheaqueousextractsasdetermined
by NMR spectroscopy (Figure 1J and K for diaphragm and
soleus and Supplementary Figures 1 and 2 for adipose and
heart). Ageing in the animals induced a decrease in glucose
and glycogen in muscle tissue with the most robust models in
the diaphragm and soleus muscle. However, differences
between genotypes were less apparent in these PLS models
when compared with the analogous model produced for
the liver.
Fatty acid metabolism is affected by the loss of
PPAR-a function
By 13 months, both GC-MS and
1H-NMR spectroscopy
indicated fatty acid accumulation in the liver. Figure 2A shows
the increase in resonances corresponding to fatty acids in the
1H-NMR spectrum of 13-month liver tissue relative to age-
matched control tissue. Although this represents only a partial
partition of the more water-soluble free fatty acids, as
determined by subsequent GC-MS analysis, these fats were
consistently increased in the extracts from PPAR-a-null mice.
GC-MS analysis of the fatty acid content of the total lipid
extracts of 13-month PPAR-a-null mice livers in conjunction
withPLS-DArevealedthattherewasalargeincreaseinlinoleic
acid (18:2), oleic acid (18:1) and di-homo-g-linolenic acid
(20:3) (Figure 2B; R
2¼0.88, Q
2¼0.45). As these models were
formed from a relatively small number of biological repeats,
the analysis was also repeated using the Student’s t-test with a
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inoleicacidanddi-homo-g-linolenicacidwerealsodetectedin
younger mice. Applying PLS-DAto theentirefattyacid data set
produced a model with ﬁve components that separated
the wild-type and PPAR-a-null mice (R
2¼0.80; Q
2¼0.61;
Figure 2C). On examining the loadings plot for component 1,
thePPAR-a-nullmiceshowedincreasedconcentrationsofoleic
acid (18:1), linoleic acid (9c, 12c-18:2) and arachidonic acid
(20:4) as determined by those fatty acids that contributed
signiﬁcantly to the loadings plot (Po0.05 for each metabolite
according to a jack kniﬁng procedure). Given that the
separation was over ﬁve components, the variable importance
to projection (VIP) scores were also considered. VIPs examine
the contribution made to the model by each variable over all
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Figure1 (A)
1H-NMRspectrashowingthedifferenceinglucoseandglycogenconcentration betweenPPAR-a-nulllivertissuesamples(black)andcontrols (blue)at3
and13months.(B)PCAplotshowingtheclusteringsof3m(opencircles),5m(opendiamonds),7m(stars),9m(opentriangles),11m(blacksquares)and13m(crosses)
liver tissue across principal component 1. Note the x-axis is the order of samples in terms of age and does not represent a principal component. (C)
1H-NMR spectra
showingthedifferenceinglucoseandglycogenconcentrationbetween3and13monthsforlivertissueextractsfromPPAR-a-nullmice.Eachspectrumistheaverageof
the ﬁve spectra obtained from all animals at that age. Key: red, 3 months; blue, 5 months; black, 11 months; green, 13 months. (D) peak area of the anomeric
1H a-
glucose (d 5.24) and glycogen (d 5.40) for spectra from the extracts of liver tissue from PPAR-a-null mice (’) and control mice (B)( E) PLS plot regressing age of
animal(y-axis) against themetabolic proﬁle of the livertissue (x-axis) in control mice asmeasured by
1H-NMR spectroscopy. PPAR-a-nullmicewere then mapped onto
thesamemodel.(F)ValidationplotofPLSmodelin(E).TrianglespredicttheR
2scoreandﬁlledsquaresare Q
2scores.Valuestotherightweretheactual valuesforthe
PLS model, whereas those on the left were formed by random permutation of the Y variable. (G) Predicted age compared with actual age for a PLS plot regressing age
oftheanimalagainstthe metabolicproﬁle ofthe livertissuein control miceasmeasured by
1H-NMR spectroscopy. PPAR-a-nullmicewere thenmappedon tothesame
model.Eachpointrepresentsthemean±standarddeviation.(H)PLSplotshowingtheage-relatedperturbationsinaqueoussolublemetabolitesoccurringinthePPAR-
a-null liver (3–13 months) measured by GC-MS with corresponding signiﬁcant metabolic changes annotated. (I) Percentage glucose in selected PPAR-a-null tissues
relative to age-matched control tissues (error bars represent standard error) *Po0.05; **Po0.01; ***Po0.001. (J) PLS plot showing the age-related perturbations in
aqueous soluble metabolites occurring in diaphragm tissue from PPAR-a-null and control mice (3–13 months) measured by NMR spectroscopy. (K) PLS plot showing
the age-related perturbations in aqueous soluble metabolites occurring in soleus tissue from PPAR-a-null and control mice (3–13 months) measured by NMR
spectroscopy. Key for all panels: B control mice; ’ PPAR-a-null mice.
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PLS component 1 were also the three fats with the highest VIP
score and were also deemed to be signiﬁcant according to jack
kniﬁng cross-validation of their VIP scores. In a similar
manner, orthogonal-PLS produced similar results (data not
shown).
Applying PLS to the fatty acid proﬁle for the liver tissue to
examine the metabolic changes that accompany ageing
produced a robust model for the combined data set (three
components; R
2Y¼0.96; Q
2¼0.90; Figure 2D). This linear
trend with age was associated with increases in the relative
concentrations of palmitic acid (16:0) and arachidonic acid
(20:4) and decreases in oleic acid (18:1) and cholesterol as the
animals’ age. This model robustly predicted age when wild-
type and null mice were compared together between 3 and 9
months (Figure 2E). However, at 11–13 months the predicted
age of the null micewassigniﬁcantly lower(Po0.01 according
to the Student’s t-test comparing the two predicted ages for
wild-type and mutant mice) for the PPAR-a-null mouse. In
part, this reﬂects the relative increase in hepatic oleic acid in
the PPAR-a-null mouse compared with wild types at any one
time point, and hence this fatty acid being relatively less
affected by the decrease associated with ageing. This model
passed cross-validation according to random permutation of
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Figure 2 (A) A section of
1H-NMR spectra (d 0.5–2.7) showing an increase in resonances corresponding to fatty acid moieties in 13-month PPAR-a-null liver tissue
(black) relative to age-matched control tissue (grey). (B) PLS-DA plot showing the clustering of 13-month PPAR-a-null liver samples (’) from controls (J) for the fatty
acidsdetectedbyGC-MS.Thecorrespondingsigniﬁcantmetabolitechangesarelabelled.(C)PLS-DAplotofthefattyacidsanalysedbyGC-MSfortheentirelivertissue
(key as in (C)). (D) A PLS plot of the regression between the fatty acid proﬁle (as measured along the x-axis) and the age of the animal (y-axis) (key as in (C)).
(E) Predicted age versus actual age for the PLS model in (D). Each point represents the mean±standard deviation. (F) Validation plot of PLS model in (E). Filled
triangles predict the R
2 score and ﬁlled squares are Q
2 scores. Values to the right were the actual values for the PLS model, whereas those on the left were formed by
random permutation of the Y variable. (G) PLS-DA of free fatty acid proﬁles in the liver tissues from PPAR-a-null and control mice at 3 months of age. (H) Validation of
PLS-DA model in (G).
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when PLS models were built for the PPAR-a-null mice or the
wild-type mice alone (data not shown).
As the fatty acid methyl ester analysis focused on total fatty
acids found within a tissue, the free fatty acid proﬁle of the
liver was also investigated using MSTFAto derivatise free fatty
acids and cholesterol derivatives prior to analysis by GC-MS.
Analysis using PLS-DA robustly discriminated PPAR-a-null
mice at 3 and 5 months of age (3 months, R
2(X)¼0.78,
Q
2¼0.88; 5 months, R
2(X)¼0.78, Q
2¼0.60; Figure 2G and H).
For both time points, this was characterised by increases in
stearate and heptadecanoic acid and decreases in oleic acid
andcholesterol.Althoughnomodelscouldbebuiltforthedata
obtained from 7- and 9-month-old animals, 11 and 13 month
groups could be distinguished (11 months, R
2(X)¼0.41,
Q
2¼0.41; 13 months, R
2(X)¼0.82, Q
2¼0.51; data not shown).
For these older animals, PPAR-a-null mice were characterised
by increased free oleic acid, linoleic acid and decreased
palmitic acid.
Figure 3A shows the differentiation of heart samples from
PPAR-a-null mice from controls by PLS-DA for all samples
regardless of age (R
2¼0.83, Q
2¼0.52) (Supplementary Table
2). Again, increases in oleic acid and linoleic acid were
importantdiscriminatorsforhearttissue from thenullmice,as
well as decreases in tetracosanoic acid (24:0), palmitic acid
(16:0), docosahexanoic acid (22:0) and arachidonic acid
(20:4). These metabolites similarly classiﬁed null from wild-
typemicewhenconsideringindividualagegroupsfrom3 to13
months (data not shown).
WATsamples from the PPAR-a-null mice were differentiated
from control samples regardless of age by PLS-DA (Figure 3B;
R
2¼0.77, Q
2¼0.48; Supplementary Table 3). The separation
was attributed to increased concentrations of eicosadienoic
acid (20:2), eicosanoic acid (20:0), tridecanoic acid (13:0),
docosadienoic acid (22:2), di-homo-g-linolenic acid (20:3) and
hexadecadienoic acid (16:2), and decreased concentrations of
octadecanoic acid (18:0), heptadecanoic acid (17:0), hexade-
cenoic acid (16:1) and tetradecenoic acid (14:1).
Using PLS analysis to examine ageing metabolic trends in
the PPAR-a-null WAT, there was a signiﬁcant age-related
increase in a number of saturated fatty acids including stearic
acid (18:0), palmitic acid (16:0), tetradecanoic acid (14:0) and
heptadecanoic acid (17:0), as well as a decrease in docosahex-
aenoic acid (22:6), which is the b-oxidation product of
tetracosahexaenoic acid (24:6) (Figure 3C). However, these
changes were similarly detected in the wild-type animals and
therefore were not a direct result of PPAR-a deletion but were
associated with normal metabolic changes associated with
ageing.
Loss of PPAR-a function causes signiﬁcant
metabolic perturbations in muscle tissue
The soleus and gastrocnemius were investigated to compare
and contrast type I (oxidative; soleus) and mixed type I/type II
(gastrocnemius) muscles by GC-MS (Supplementary
Figure 3a) and NMR (Supplementary Figure 3b). Analysis of
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Figure3 PLS-DAplotsshowingthedifferentiationof3–13monthPPAR-a-null(’)andcontrol(J)samplesin(A)hearttissueand(B)whiteadiposetissuefollowing
methylesteriﬁcationofthefattyacidcomplement,andanalysisbyGC-MS.(C)PLSplotshowingtheage-relatedperturbationsinlipidmetabolitesoccurringinthePPAR-
a-null WAT (3–13 months) with corresponding signiﬁcant metabolic changes annotated. (D) PLS coefﬁcient values showing the contribution of selected metabolites to
age-related metabolic trends in the gastrocnemius, soleus, heart and diaphragm in the PPAR-a-null mouse. All coefﬁcients shown are signiﬁcant at the 95% conﬁdence
limit. Error bars indicate standard error.
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increased concentration of lactate and a decreased concentra-
tion of creatine at all time points examined. In the gastro-
cnemius,increasedconcentrations ofalanine andlactate anda
decreased concentration of creatine characterised the null
mouse (data not shown).
PLS analysis of both the soleus and gastrocnemius muscle
from the PPAR-a-null mouse showed a signiﬁcant age-related
increaseincreatineconcentration,andaconcomitantdecrease
in lactate and glutamate in both tissues, as well as additional
decreases in alanine and glutamine in the soleus only
(Figure 3D). Similar perturbations were also observed in the
heart and diaphragm; the concentration of creatine increased,
whereas alanine and lactate concentrations decreased sig-
niﬁcantly with age in these tissues (Figure 3D). Interestingly,
the soleus muscle also showed an age-related increase in the
concentrations of stearic acid (18:0) and palmitic acid (16:0)
(data not shown).
GC-MS analysis of the heart also showed a reduction in
b-hydroxybutyrate, a ketonebody used to supply energy to the
heart under conditions of low glucose intake. This reduction
was evident at 5 and 9 months (data not shown). A complete
list of the most signiﬁcant changes is available as part of the
online Supplementary Tables 1–9 and summarised in Figure 4.
Discussion
Differential expression of genes encoding enzymes involved
in mitochondrial and peroxisomal fatty acid oxidation
constitutes well-characterised alterations in the PPAR-a-null
mouse (reviewed in Mandard et al, 2004). Despite this,
previous studies on this mouse have largely reported no
obvious phenotype unless fasted, under which conditions the
defects in fatty acid oxidation, gluconeogenesis and ketogen-
esis result in an increase in the concentration of circulating
free fatty acid levels, hypoglycaemia, hypoketonaemia and
hypothermia (Djouadi et al, 1998; Kersten et al, 1999;
Leone et al, 1999), or under high fat feeding conditions where
the heart has decreased myocardial fatty acid oxidation and
someevidenceofage-relatedcardiomyopathy(Watanabeetal,
2000). In this study, we demonstrate that the unchallenged
PPAR-a-null mouse fed ad libitum possesses underlying
perturbations in metabolism, which are attributable to
reduced glucose and glycogen storage in the liver and
alterations in the metabolism of fatty acids. We also identiﬁed
a number of metabolic changes associated with ageing in both
mouse genotypes and these either exacerbated or reduced the
effects of genetic modiﬁcation as the PPAR-a-null mice aged.
To examine ageing trends in both mouse genotypes, the
multivariate statistical approach of PLS was used. This
algorithm determines the linear (or polynomial) correlation
between a dependent variable or variables (Y) and a matrix of
predictor variables (X). In this study, we have used this
approach to determine the metabolic changes associated with
ageing in both wild-type and PPAR-a knockout mice. These
trends were robust enough to predict the age of the animal
fromthemetabolicproﬁlesofthetissuebeingexaminedforthe
liver, muscle and heart tissue. Furthermore, by producing
models from tissues of wild-type animals only, the proﬁles of
tissue from the PPAR-a-null mice can be examined to see
whether these ageing trends are also present. In the liver
tissue, regardless of genotype, ageing was characterised by a
decrease in glucose and glycogen in the aqueous extracts and
increases in palmitic acid (16:0) and arachidonic acid (20:4)
and decreases in oleic acid (18:1) and cholesterol in the lipid
extracts. However, although these metabolic changes could be
used to age animals according to the metabolic proﬁles of their
tissues, it is important to stress that deviations from the trend
do not mean that the ageing process in an animal is either
increased or decreased. Rather this process has detected an
interaction between the metabolic changes that accompany
ageing and those that accompany the genetic modiﬁcation.
In addition to the decrease in liver glucose and glycogen
detected by PLS in both mouse strains with age, metabolic
changes detected in the liver of PPAR-a-null mice are
consistent with reduced glucose storage and production by
gluconeogenesis. The combination of these effects resulted in
Age-related metabolic perturbations in the PPAR-α-null mouse
Heart
Liver
Gastrocnemius
Soleus
WAT
Diaphragm
Decreased glucose
Decreased lactate and alanine
Decreased ketone supply
Decreased FAO
Increased creatine
Decreased glucose storage
Decreased gluconeogenesis
Decreased cholesterol synthesis
Increased FA accumulation
Decreased glycogen
Increased creatine
Decreased glucose and glycogen
Increased creatine
Increased saturated FAs
Decreased glucose
Increased saturated FAs
Decreased glucose and glycogen
Decreased lactate and alanine
Increased creatine
Figure 4 A summary ﬁgure of the key changes between wild-type and PPAR-a-null mice and associated with ageing in both mouse genotypes.
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mice, similar to that induced by fasting in the younger mouse,
where liver glucose and glycogen were markedly reduced.
Under conditions of low hepatic glycogen concentrations, as
observed here in the older mice, the liver may use lactate and
amino acids such as alanine and glutamine for continued
glucose biosynthesis (Kaloyianni and Freedland, 1990). In this
study, we observed an age-related increase in hepatic alanine
and lactate concentrations which suggest that, although these
gluconeogenic precursors are present in the liver, there is a
failure to convert them to glucose, which is most likely to be a
consequence of the reduced glucose-6-phosphatase (G6pc)
and phosphoenolpyruvate carboxykinase 1 (Pck1) expression
(see below and Supplementary information). This effect in
turn is likely to exacerbate the hypoglycaemia observed in the
ageing PPAR-a-null mouse. Xu et al (2002) have previously
investigated impaired gluconeogenesis in the liver in young
(4 month old) mice under fed and fasted conditions,
demonstrating a reduction in the production of glucose from
lactate under both conditions.
To further characterise the reduction in gluconeogenesis,
RT–PCR was performed to measure the expression of key
genes involved in this pathway (Supplementary information).
Consistent with reduced gluconeogenesis, we observed a
2.7-fold reduction in the transcription of G6pc, and a 5-fold
reductioninPck1,thelatterexertingahighdegreeofmetabolic
control over the gluconeogenic pathway. G6pc expression is in
partcontrolledbyPPAR-gcoactivator1(Ppargc1a)(Soyaletal,
2006), which was also reduced two-fold. The perturbation in
glucose ﬂux may in turn also account for the reduced
expression of 6-phosphofructo-2-kinase/fructose-2,6-bipho-
sphatase (Pfkf3b), a key enzyme in the control of glycolysis
and gluconeogenesis.
There was a concomitant age-related decrease in lactate in
all muscle tissues analysed, and alanine in the soleus, heart
and diaphragm. The concentration of glucose was also seen to
decrease signiﬁcantly in an age-dependant manner in both the
soleus and diaphragm. Taken together, these ﬁndings are
consistent with a reduction in glycolysis in muscle tissue.
Interestingly, the soleus muscle also showed an age-related
increase in stearic acid and palmitic acid concentrations.
Unlike the gastrocnemius, which is composed of both type I
(oxidative) and type II (glycolytic) muscle ﬁbres, the soleus is
composedsolelyoftypeImuscleﬁbres,whichprimarilystores
fuel in the form of triglyceride.
Fatty acids represent an alternative energy source, which
allows glucose to be spared for tissues such as brain that are
unable to metabolise signiﬁcant amounts of fatty acids. In the
liver, fatty acids can be metabolised ultimately through the
TCA cycle to generate ATP, or can be used for ketogenesis. As
PPAR-a controls the expression of many enzymes involved in
both the b-oxidation and ketogenic pathways, fatty acids
accumulate in the livers of PPAR-a-deﬁcient mice (Hashimoto
et al, 2000). An age-related accumulation of fatty acids
was detected in the livers of the PPAR-a-null mice by both
NMR spectroscopy and GC-MS. Patsouris et al (2006) have
previouslyreportedanincreaseinhepatictriglycerideinPPAR-
a-null mice. However, when considering the total fatty acid
complement of the liver tissue, the major fatty acid changes
that characterised the PPAR-a-null mouse were also fatty acids
that changed during the normal process of ageing. In
particular, oleate was increased in the livers of PPAR-a-null
mice at individual time points, but it also decreased with age.
In contrast to the changes we detected in the aqueous
metabolite complement of liver tissue, the net effect of these
two metabolic perturbations in lipid metabolism in the liver
were that the 13-month-old PPAR-a-null mice appeared to be
younger than their wild-type controls when aged through their
lipid proﬁles. Oleate increases in the liver of the PPAR-a-null
mouse because several of the enzymes involved in the
subsequent metabolism of this fatty acid, including the
elongases, Elovl-5 and -6, and the D5 and D6 desaturases,
which produce polyunsaturated fats such as arachidonic acid,
are partly under the regulation of PPAR-a. Oleate is also found
in high concentrations in liver TAGs, suggesting that the
observed steatosis may be exacerbated by the increased oleate
found in the PPAR-a-null mouse.
Analysis of fatty acids using fatty acid methyl esteriﬁcation
producesadatasetreﬂectingthetotalfattyacidcomplementof
a tissue. Although for many tissues this reﬂects triglyceride
deposits it will also be inﬂuenced by cell membrane and non-
esteriﬁed free fatty acids. In the liver, NEFAs and cholesterol
derivatives were also measured. This approach produced
some interesting differences compared with the total fatty acid
complement with young PPAR-a-null mice being characterised
by a decreased oleate/stearate ratio, in keeping with the fact
that stearoyl-CoA desaturase (SCD) is in part under PPAR-a
control. Furthermore, cholesterol was also decreased in young
PPAR-a-null mice and again cholesterol synthesis is in part
regulated by PPAR-a, particularly with respect to diurnal
variation in cholesterol synthesis (Patel et al, 2001). No
difference was found in mice between 7 and 9 months of age
but at 11–13 months of age again PPAR-a-null mice were
distinguished by their free fatty acid proﬁle, but this time by
increased oleic acid, linoleic acid and decreased palmitic acid.
The increase in oleic acid now mirrored the global increase
detected in this fattyacid, suggesting that this changewas now
determined by the accumulation of triglyceride in the liver
rather than which enzymes were under PPAR-a control.
Hearts of the PPAR-a-null mice exhibited signs of perturbed
energy homoeostasis associated with a reduced supply of
ketone bodies. Heart tissue from the PPAR-a-null mouse had
decreased b-hydroxybutyrate, reﬂecting the well-documented
decline in ketogenesis (Kersten et al, 2000; Barak and Kim,
2007). As evidence of perturbed fatty acid synthesis in the
PPAR-a-null mouse, there was a consistent increase in linoleic
acid, and a decrease in arachidonic acid at the majority of time
points studied. Linoleic acid is converted to arachidonic acid
throughelongases and desaturases,enzymestheexpression of
which are partly under the control of PPAR-a (Wang et al,
2006).
The metabolomic analysis of the WATrevealed an increase
in the concentration of several saturated fatty acids with age
consistent with a reduction in SCD activity, the expression of
which is, in part, controlled by PPAR-a (Wang et al, 2006).
However, these changes occurred in the WATof both null and
wild-type mice, indicating that the reductions in SCD activity
occur as part of the normal ageing process, and may actually
be the result of an age-related decrease in PPAR-g expression
(Ye et al, 2006) which, in part, controls the expression of SCD
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in adipose tissue than PPAR-a (Braissant et al, 1996).
In conclusion, our metabolomic study demonstrates that a
loss of PPAR-a results in a marked reduction in hepatic
glucose/glycogen and subsequent hepatic steatosis with age.
This is also accompanied by decreased glucose metabolism
and a reduction in the synthesis of polyunsaturated fats across
the whole organism. These changes interact with the normal
metabolic changes that accompany ageing, which either
magnify or diminish the metabolic perturbations detected,
demonstrating that the study of any genetic modiﬁcation
should be placed in context with the normal ageing process.
Materials and methods
Tissue collection
All animal procedures conformed to the guidelines determined by the
UK Home Ofﬁce for animal welfare. Tissues from wild-type SVEV/129
mice and PPAR-a-null mice were obtained from stable colonies at the
University of Oxford (n¼5; 3, 5, 7, 9, 11 and 13 months age). Mice
were fed standard laboratory chow ad libitum prior to death (Special
Diet Services, Essex, UK). Mice were injected subcutaneously with a
0.3ml mixture of medetomidine (10%; Pﬁzer Limited, Kent, UK),
ketamine (7.6%; Ve ´toquinol UK Limited, Bicester, UK) in sterile
water, andtissuecollectionwasperformedafterthelossofcornealand
pedal reﬂexes. Abdominal WAT, hearts, livers, skeletal muscle
(gastrocnemius and soleus) and diaphragms were rapidly dissected
(o60s post-mortem time prior to freezing), frozen in liquid nitrogen
and stored at  801C.
Metabolomics analyses
Tissueswereextractedusingamethanol–chloroform–waterextraction
procedure to separate aqueous-soluble metabolites from lipids as
described previously (Atherton et al, 2006). Brieﬂy, B100mg tissue
were pulverised with dry ice. Here, 600ml methanol–chloroform (2:1)
was added and the samples were sonicated for 15min. Water and
chloroform were added (200ml of each) and the samples were
centrifuged for 20min. The resulting aqueous and organic layers were
separated from the protein pellet. The organic layer was dried
overnight in a fume hood, whereas the aqueous extracts were
evaporated to dryness using an evacuated centrifuge (Eppendorf,
Hamburg, Germany).
NMR spectroscopy
The dried aqueous extracts were rehydrated in 600mlD 2O, buffered in
0.24M sodium phosphate (pH 7.0) containing 1mM (sodium-3-(tri-
methylsilyl)-2,2,3,3-tetradeuteriopropionate (TSP) (Cambridge Iso-
tope Laboratories Inc., Andover, MA, USA) as an internal standard.
The samples were analysed using an INOVA spectrometer operating at
400.13MHz for the
1H frequency (Varian, CA, USA) using a 5-mm
broadband inverse probe. Spectra were collected using a solvent
suppression pulse sequence based on a one-dimensional NOESYpulse
sequence to saturate the residual
1H water proton signal (relaxation
delay¼2s, t1¼3ms, mixing time¼150ms, solvent presaturation ap-
plied during the relaxation time and the mixing time). In total, 128
transients were collected into 16K data points over a spectral width of
12p.p.m. at 371C. For this assay, the coefﬁcients of variation for
variousmetabolitesdetectedin the extracts of livertissueareshown in
the Supplementary information.
GC-MS
Aqueous samples were derivatised using the procedure reported by
Gullberg et al (2004). An aliquot of 150ml of the D2O sample used for
1H-NMR spectroscopy was evaporated to dryness in an evacuated
centrifuge and 30ml methoxyamine hydrochloride (20mgml
 1 in
pyridine) was added. The samples were vortex mixed for 1min, and
derivatised at room temperature for 17h. Samples were then silylated
with 30mlo fN-methyl-N-trimethylsilyltriﬂuoroacetamide for 1h at
room temperature. The derivatised samples were diluted (1:10) with
hexane prior to GC-MS analysis.
Organic-phase metabolites were derivatised by acid catalysed
esteriﬁcation (Morrison and Smith, 1964). Lipids were dissolved
in 0.25ml of chloroform/methanol (1:1 v/v). An aliquot of 0.10ml
BF3/methanol (Sigma-Aldrich) was added and the vials were
incubated at 801C for 90min. Once cool 0.3ml H2O (mQ) and 0.6ml
hexane were added and each vial was vortex mixed for 1min. The
aqueous layer was discarded and the remaining organic layer was
evaporated to dryness before reconstitution in 200ml hexane for
analysis.
The derivatised aqueous samples were injected into a Thermo
Electron Trace GC Ultra equipped with a 30m 0.25mm ID 5% phenyl
polysilphenylene-siloxane column with a chemically bonded 25mmT R -
5MS stationary phase (Thermo Electron Corporation; injector
temperature¼2201C, helium carrier gas ﬂow rate¼1.2mlmin
 1). The
initial column temperature was 701C; this was held for 2min and then
increased by 51Cmin
 1 to 3101Ca n dw a sh e l df o r2 0m i n .
The derivatised organic metabolites were injected onto a ZB-WAX
column (30m 0.25mm ID 0.25mm df; 100% polyethylene glycol).
The initial column temperature was 601C; this was held for 2min and
then increased by 101Cmin
 1 to 1501C and then by 41Cmin
 1 up to a
temperature of 2301C where it was held for 7min.
The column eluent was introduced into a DSQ quadrupole
mass spectrometer (Thermo Electron Corporation) (transfer line
temperature¼3101C for aqueous metabolites and 2401C for lipid
metabolites, ion source temperature¼2501C, electron beam¼70eV).
The detector was turned on after a solvent delay of 240s and data
were collected in full-scan mode using three scans per second
across a mass range of 50–650 m/z. For this assay, the coefﬁcients of
variation for various fatty acids are shown in the Supplementary
information.
Data analysis
NMR spectra were processed using ACD SpecManager 1D NMR
processor (version 8; ACD, Toronto, Canada). Spectra were Fourier
transformedfollowing multiplication bya line broadening of 1Hz,and
referenced to TSP at 0.0p.p.m. Spectra were phased and baseline
corrected manually. Each spectrum was integrated using 0.04p.p.m.
integral regions between 0.5–4.5 and 5.1–10.0p.p.m. To account for
any difference in concentration between samples, each spectral region
was normalised to a total integral value of 10000.
GC-MS chromatograms were analysed using Xcalibur (v. 2.0;
Thermo Fisher Corp.), integrating each peak individually. Peaks were
normalised so that the total sum of peaks was set to 10000.
Deconvolution of overlapping peaks was achieved by generating
traces of selected ions. A 0.1-min threshold window was used for the
deviation of peaks away from the predicted retention time across the
data set. Structures were assigned using both the NIST database of
mass spectra and analysis of standard compounds.
Data sets were imported into SIMCA-P 10.0 (Umetrics, Umea ˚,
Sweden) for processing using PCA, PLS (a regression extension of
PCA used to separate out a trend from other variation in the data
set) and PLS-DA (a regression extension of PCA used for classiﬁca-
tion). Identiﬁcation of major metabolic perturbations within the
pattern recognition models was achieved by the analysis of
correspondingloading plots. PLSplots were usedto identifyvariations
correlated with age. Additionally, R
2 and Q
2 were used as measures
for the robustness of a pattern recognition model. R
2 is the fraction
of variance explained by a component, and cross-validation of
R
2 gives Q
2, which reveals the fraction of the total variation predicted
by a component. Both values are indicative of how good the overall
model is. Typically, a robust model has R
240.50 and Q
240.40.
Coefﬁcient scores rank the observations according to their contribu-
tion to the model. To conﬁrm which metabolites contributed
signiﬁcantly to each model, each variable was assessed by a jack-
kniﬁng routine to assess its contribution to a given component. Only
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were included.
The overall strategy for data analysis was as follows. Metabolite
differences ata given agewere determined by producing a PLS-DA plot
comparing wild-type and null mice and taking those metabolites that
made a signiﬁcant contribution to the ﬁrst PLS-DA component
provided that the model was deemed to have a sufﬁciently robust Q
2
(40.40). In addition, PLS was used to regress the age of the animal
against the metabolic proﬁle for that tissue. This was performed on
both wild-type and null mice.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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